Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease

BMC Gastroenterology
Anna-Maria SchneiderJudith Pichler

Abstract

Vedolizumab is safe and effective in adult patients with Crohn's disease (CD) and ulcerative colitis (UC); however, data in children with inflammatory bowel disease (IBD) are scarce. Therefore, we evaluated vedolizumab use in a cohort of Austrian paediatric patients with IBD. Twelve patients (7 female; 7 CD; 5 UC), aged 8-17 years (median, 15 years), with severe IBD who received vedolizumab after tumour necrosis factor α antagonist treatment were retrospectively analysed. Clinical activity scores, relevant laboratory parameters, and auxological measures were obtained at infusion visits. In the CD group, 1/7 patient discontinued therapy due to a severe systemic allergic reaction; 1/7 and 2/7 patients achieved complete and partial response, respectively, at week 14; and 3/7 patients discontinued therapy due to a primary non-response or loss of response. In the UC group, complete clinical remission was achieved at weeks 2, 6, and 14 in 2/5, 1/5 and 1/5 patients respectively; partial response was observed in one patient at week 2. CD activity scores did not significantly change from baseline to week 38 (median 47.5 vs. 40 points, p = 1,0), while median UC activity scores changed from 70 to 5 points (p < 0,001). Substantial weight g...Continue Reading

References

Apr 16, 1999·Journal of Pediatric Gastroenterology and Nutrition·A M GriffithsP M Sherman
May 15, 2007·Lancet·Daniel C Baumgart, Simon R Carding
Mar 8, 2008·Molecular Nutrition & Food Research·Michael D Kappelman, Athos Bousvaros
Sep 3, 2010·Inflammatory Bowel Diseases·Michael D KappelmanPeter Margolis
May 9, 2012·Gastroenterology·Jeffrey S HyamsAndreas Lazar
Nov 15, 2012·Scandinavian Journal of Gastroenterology·Anssi HämäläinenKaija-Leena Kolho
Jan 19, 2013·Inflammatory Bowel Diseases·Paolo BiancheriThomas T MacDonald
Jun 6, 2013·Gastroenterology·William J SandbornUNKNOWN PURSUIT-SC Study Group
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Jun 10, 2014·Journal of Crohn's & Colitis·F M RuemmeleUNKNOWN European Society of Pediatric Gastroenterology, Hepatology and Nutrition
Aug 20, 2015·Inflammatory Bowel Diseases·Edward SheltonVijay Yajnik
Mar 22, 2016·International Journal of Medical Microbiology : IJMM·Claudia GüntherJan Wehkamp
Aug 20, 2016·Inflammatory Bowel Diseases·Namita SinghMarla C Dubinsky
Sep 7, 2016·Inflammatory Bowel Diseases·Máire A ConradJudith R Kelsen

❮ Previous
Next ❯

Citations

Oct 28, 2019·Expert Opinion on Biological Therapy·Logan Jerger, Jeffrey S Hyams
Dec 31, 2019·F1000Research·Bhaskar Gurram, Ashish S Patel
Nov 19, 2019·Journal of Pediatric Gastroenterology and Nutrition·Jacqueline JossenMarla C Dubinsky
Jul 9, 2020·Journal of Pediatric Gastroenterology and Nutrition·Martine A AardoomJohanna C Escher
Jan 31, 2020·Current Gastroenterology Reports·Joshua M Steinberg, Aline Charabaty
Oct 12, 2020·Clinical Journal of Gastroenterology·Aiko IkeuchiMuneaki Matsuo
Oct 31, 2020·Inflammatory Bowel Diseases·Michael T DolingerMarla C Dubinsky
Jul 13, 2020·Biochemical Pharmacology·Gabor TajtiRaymond S Norton
Apr 6, 2021·Frontiers in Pediatrics·Eirini GiannoudakiPatrick T Walsh
Aug 14, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Francesca PenaginiGian Vincenzo Zuccotti
Nov 2, 2021·International Journal of Hematology·Kyohei IsshikiHirokazu Kanegane

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Software Mentioned

VEDOKIDS
R Core Team
R

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.